Accompanying these findings is a call for refined treatment strategies that have potential to better outcomes among patients ...

In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival ...

Patients experienced similar safety and efficacy if they received first-line or later-line treatment for unresectable ...

“We found that the probability of being alive and free of disease at two years was approximately 64% for cetuximab versus 51% ...

While cetuximab is a commonly used alternative, its efficacy has been questioned. Immune checkpoint inhibitors, such as ...

Cisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but nearly a third of patients can't tolerate ...

Head and neck cancers are the seventh most common type of cancer worldwide, according to the 2020 World Cancer Report.

Source: Getty Images Perioperative durvalumab has “the potential to transform the standard of care” for patients with muscle-invasive bladder cancer, according to Thomas Powles, MBBS ...